Recent Advances in Glycosylated Hemoglobin Measurements

Goldstein, David E.; Wiedmeyer, Hsiao-Mei; England, J D; Little, Randie R.; Parker, Kayla

doi:10.3109/10408368409165782

Cited by 29 publications

(14 citation statements)

References 171 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Conversely, HbA1c, the major protein found in erythrocytes, has been used as a clinical diagnostic marker of relatively long-term (∼90 days) glucose control in diabetic patients since the 1970s. 17 With a life span of 120 days, erythrocytes can accumulate relatively high amounts of the Amadori compound, particularly on the cell membrane proteins, which are in close contact with glucose throughout their life cycle. As a result, it is possible that some glycated erythrocyte membrane proteins may provide a more sensitive biomarker of glycemic control.…”

Section: Introductionmentioning

confidence: 99%

Proteomic Profiling of Nonenzymatically Glycated Proteins in Human Plasma and Erythrocyte Membranes

et al. 2008

View full text Add to dashboard Cite

Nonenzymatic glycation of peptides and proteins by D-glucose has important implications in the pathogenesis of diabetes mellitus, particularly in the development of diabetic complications. In this work, we report the first proteomics-based characterization of nonenzymatically glycated proteins in human plasma and erythrocyte membranes from individuals with normal glucose tolerance, impaired glucose tolerance, and type 2 diabetes mellitus. Phenylboronate affinity chromatography was used to enrich glycated proteins and glycated tryptic peptides from both human plasma and erythrocyte membranes. The enriched peptides were subsequently analyzed by liquid chromatography coupled with electron transfer dissociation-tandem mass spectrometry, resulting in the confident identification of 76 and 31 proteins from human plasma and erythrocyte membranes, respectively. Although most of the glycated proteins could be identified in samples from individuals with normal glucose tolerance, slightly higher numbers of glycated proteins and more glycation sites were identified in samples from individuals with impaired glucose tolerance and type 2 diabetes mellitus.

show abstract

Section: Introductionmentioning

confidence: 99%

Proteomic Profiling of Nonenzymatically Glycated Proteins in Human Plasma and Erythrocyte Membranes

et al. 2008

View full text Add to dashboard Cite

show abstract

“…Blindness, kidney failure, amputation of the lower limbs, and nerve damage are only some of the major consequences of diabetes. Long periods of hyperglycaemia account for these long-term complications but also hypoglycaemia (blood glucose level below 50 mg/dl) represents a major issue in diabetes therapy since it can cause sudden coma and brain damage [1], [2]. Development of these complications can be prevented or slowed down by controlling the blood glucose level.…”

Section: Introductionmentioning

confidence: 99%

Ex Vivo Continuous Glucose Monitoring With Microdialysis Technique: The Example of GlucoDay

2008

View full text Add to dashboard Cite

The use of a glucose biosensor in conjunction with a microdialysis probe used to sample the interstitial fluid of the patient has been demonstrated to be extremely useful and advantageous for obtaining a continuous glucose monitoring instrument capable of detecting glycemic level in real time for a long period. The first example of this kind of instrument which was cleared for commercialization is the GlucoDay made by Menarini. The approach used by the GlucoDay presents several advantages if compared with other instruments and its features and future prospective are thoroughly discussed.

show abstract

“…Blindness, kidney failure, amputation of the lower limbs and nerve damage are only some of the major consequences of diabetes. Long periods of hyperglycaemic account for these long-term complications but also hypoglycaemia (blood glucose level below 50 mg/dl) represents a major issue in diabetes therapy since it can cause sudden coma and brain damage (Goldstein et al, 1984;Zimmermann et al, 2003). Development of these complications can be prevented or slowed down by controlling blood glucose level.…”

Section: Introductionmentioning

confidence: 99%

Novel planar glucose biosensors for continuous monitoring use

Ricci

Moscone

Tuță

et al. 2005

Biosensors and Bioelectronics

View full text Add to dashboard Cite

Novel planar glucose biosensors to be used for continuous monitoring have been developed. The electrodes are produced with the "screen printing" technique, and present a high degree of reproducibility together with a low cost and the possibility of mass production. Prior to enzyme immobilisation, electrodes are chemically modified with ferric hexacyanoferrate (Prussian Blue). This allows the detection of the hydrogen peroxide produced by the enzymatic reaction catalysed by GOD, at low applied potential (ca. 0.0 V versus Ag/AgCl), highly limiting any electrochemical interferences. The layer of Prussian Blue (PB) showed a high stability at the working conditions (pH 7.4) and also after 1 year of storage dry at RT, no loss of activity was observed. The assembled glucose biosensors, showed high sensitivity towards glucose together with a long-term operational and storage stability. In a continuous flow system, with all the analytical parameters optimised, the glucose biosensors detected glucose concentration as low as 0.025 mM with a linear range up to 1.0 mM.These probes were also tested over 50-60 h in a continuous flow mode to evaluate their operational stability. A 0.5 mM concentration of glucose was continuously fluxed into a biosensor wall-jet cell and the current due to the hydrogen peroxide reduction was continuously monitored. After 50-60 h, the drift of the signal observed was around 30%.Because of their high stability, these sensors suggest the possibility of using such biosensors, in conjunction with a microdialysis probe, for a continuous monitoring of glucose for clinical purposes.

show abstract

Recent Advances in Glycosylated Hemoglobin Measurements

Cited by 29 publications

References 171 publications

Proteomic Profiling of Nonenzymatically Glycated Proteins in Human Plasma and Erythrocyte Membranes

Proteomic Profiling of Nonenzymatically Glycated Proteins in Human Plasma and Erythrocyte Membranes

Ex Vivo Continuous Glucose Monitoring With Microdialysis Technique: The Example of GlucoDay

Novel planar glucose biosensors for continuous monitoring use

Contact Info

Product

Resources

About